{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:36:50Z","timestamp":1792129010762,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI169739"],"award-info":[{"award-number":["R01 AI169739"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI169739"],"award-info":[{"award-number":["R01 AI169739"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI169739"],"award-info":[{"award-number":["R01 AI169739"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI169739"],"award-info":[{"award-number":["R01 AI169739"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201800049C"],"award-info":[{"award-number":["HHSN272201800049C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI169739"],"award-info":[{"award-number":["R01 AI169739"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI169739"],"award-info":[{"award-number":["R01 AI169739"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["K12 GM088021"],"award-info":[{"award-number":["K12 GM088021"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20 GM121176"],"award-info":[{"award-number":["P20 GM121176"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01241-7","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:33:25Z","timestamp":1753878805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Virus-like particle vaccines targeting a key epitope in circumsporozoite protein provide sterilizing immunity against malaria"],"prefix":"10.1038","volume":"10","author":[{"given":"Yogesh","family":"Nepal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Francian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevel","family":"Flores-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce T.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil A.","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fidel","family":"Zavala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce","family":"Chackerian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"1241_CR1","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1016\/S2666-5247(24)00016-8","volume":"5","author":"P Venkatesan","year":"2024","unstructured":"Venkatesan, P. The 2023 WHO world malaria report. Lancet Microbe 5, e214 (2024).","journal-title":"Lancet Microbe"},{"key":"1241_CR2","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1038\/s41591-023-02641-9","volume":"29","author":"T Emiru","year":"2023","unstructured":"Emiru, T. et al. Evidence for a role of Anopheles stephensi in the spread of drug- and diagnosis-resistant malaria in Africa. Nat. Med. 29, 3203\u20133211 (2023).","journal-title":"Nat. Med."},{"key":"1241_CR3","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.pt.2024.04.016","volume":"40","author":"PA Hancock","year":"2024","unstructured":"Hancock, P. A., Ochomo, E. & Messenger, L. A. Genetic surveillance of insecticide resistance in African Anopheles populations to inform malaria vector control. Trends Parasitol. 40, 604\u2013618 (2024).","journal-title":"Trends Parasitol."},{"key":"1241_CR4","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40121-022-00647-3","volume":"11","author":"JC Semenza","year":"2022","unstructured":"Semenza, J. C., Rocklov, J. & Ebi, K. L. Climate change and cascading risks from infectious disease. Infect. Dis. Ther. 11, 1371\u20131390 (2022).","journal-title":"Infect. Dis. Ther."},{"key":"1241_CR5","doi-asserted-by":"crossref","unstructured":"White, N. J. & Chotivanich, K. Artemisinin-resistant malaria. Clin. Microbiol. Rev. 37, e0010924 (2024).","DOI":"10.1128\/cmr.00109-24"},{"key":"1241_CR6","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1084\/jem.177.5.1287","volume":"177","author":"U Frevert","year":"1993","unstructured":"Frevert, U. et al. Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J. Exp. Med 177, 1287\u20131298 (1993).","journal-title":"J. Exp. Med"},{"key":"1241_CR7","doi-asserted-by":"publisher","first-page":"26784","DOI":"10.1074\/jbc.M104038200","volume":"276","author":"C Pinzon-Ortiz","year":"2001","unstructured":"Pinzon-Ortiz, C., Friedman, J., Esko, J. & Sinnis, P. The binding of the circumsporozoite protein to cell surface heparan sulfate proteoglycans is required for plasmodium sporozoite attachment to target cells. J. Biol. Chem. 276, 26784\u201326791 (2001).","journal-title":"J. Biol. Chem."},{"key":"1241_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161607","volume":"11","author":"J Zhao","year":"2016","unstructured":"Zhao, J., Bhanot, P., Hu, J. & Wang, Q. A Comprehensive Analysis of Plasmodium Circumsporozoite Protein Binding to Hepatocytes. PLoS One 11, e0161607 (2016).","journal-title":"PLoS One"},{"key":"1241_CR9","doi-asserted-by":"crossref","unstructured":"Flores-Garcia, Y. et al. Antibody-mediated protection against plasmodium sporozoites begins at the dermal inoculation site. mBio 9, e02194 (2018).","DOI":"10.1128\/mBio.02194-18"},{"key":"1241_CR10","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41590-018-0228-6","volume":"19","author":"IA Cockburn","year":"2018","unstructured":"Cockburn, I. A. & Seder, R. A. Malaria prevention: from immunological concepts to effective vaccines and protective antibodies. Nat. Immunol. 19, 1199\u20131211 (2018).","journal-title":"Nat. Immunol."},{"key":"1241_CR11","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41579-024-01065-7","volume":"22","author":"PE Duffy","year":"2024","unstructured":"Duffy, P. E., Gorres, J. P., Healy, S. A. & Fried, M. Malaria vaccines: a new era of prevention and control. Nat. Rev. Microbiol. 22, 756\u2013772 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"1241_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS, S Clinical Trials Partnership","year":"2015","unstructured":"RTS, S Clinical Trials Partnership Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","journal-title":"Lancet"},{"key":"1241_CR13","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","volume":"15","author":"MT White","year":"2015","unstructured":"White, M. T. et al. Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect. Dis. 15, 1450\u20131458 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"1241_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","volume":"403","author":"MS Datoo","year":"2024","unstructured":"Datoo, M. S. et al. Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 403, 533\u2013544 (2024).","journal-title":"Lancet"},{"key":"1241_CR15","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(13)62238-2","volume":"382","author":"VS Moorthy","year":"2013","unstructured":"Moorthy, V. S., Newman, R. D. & Okwo-Bele, J. M. Malaria vaccine technology roadmap. Lancet 382, 1700\u20131701 (2013).","journal-title":"Lancet"},{"key":"1241_CR16","doi-asserted-by":"publisher","first-page":"e1010409","DOI":"10.1371\/journal.ppat.1010409","volume":"18","author":"N Beutler","year":"2022","unstructured":"Beutler, N. et al. A novel CSP C-terminal epitope targeted by an antibody with protective activity against plasmodium falciparum. PLoS Pathog. 18, e1010409 (2022).","journal-title":"PLoS Pathog."},{"key":"1241_CR17","doi-asserted-by":"crossref","unstructured":"Singer, M., Kanatani, S., Castillo, S. G., Frischknecht, F. & Sinnis, P. The Plasmodium circumsporozoite protein. Trends Parasitol. 40, 1124\u20131134 (2024).","DOI":"10.1016\/j.pt.2024.10.017"},{"key":"1241_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1126\/science.6204383","volume":"225","author":"JB Dame","year":"1984","unstructured":"Dame, J. B. et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225, 593\u2013599 (1984).","journal-title":"Science"},{"key":"1241_CR19","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1126\/science.2409595","volume":"228","author":"F Zavala","year":"1985","unstructured":"Zavala, F. et al. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 228, 1436\u20131440 (1985).","journal-title":"Science"},{"key":"1241_CR20","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1093\/infdis\/171.6.1576","volume":"171","author":"DM Gordon","year":"1995","unstructured":"Gordon, D. M. et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171, 1576\u20131585 (1995).","journal-title":"J. Infect. Dis."},{"key":"1241_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/srep46621","volume":"7","author":"KA Collins","year":"2017","unstructured":"Collins, K. A., Snaith, R., Cottingham, M. G., Gilbert, S. C. & Hill, A. V. S. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci. Rep. 7, 46621 (2017).","journal-title":"Sci. Rep."},{"key":"1241_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108996","volume":"35","author":"D Chatterjee","year":"2021","unstructured":"Chatterjee, D. et al. Avid binding by B cells to the Plasmodium circumsporozoite protein repeat suppresses responses to protective subdominant epitopes. Cell Rep. 35, 108996 (2021).","journal-title":"Cell Rep."},{"key":"1241_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1172\/JCI70349","volume":"124","author":"L Foquet","year":"2014","unstructured":"Foquet, L. et al. Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. J. Clin. Invest 124, 140\u2013144 (2014).","journal-title":"J. Clin. Invest"},{"key":"1241_CR24","doi-asserted-by":"publisher","first-page":"909","DOI":"10.4049\/jimmunol.132.2.909","volume":"132","author":"MR Hollingdale","year":"1984","unstructured":"Hollingdale, M. R., Nardin, E. H., Tharavanij, S., Schwartz, A. L. & Nussenzweig, R. S. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J. Immunol. 132, 909\u2013913 (1984).","journal-title":"J. Immunol."},{"key":"1241_CR25","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41590-024-01938-2","volume":"25","author":"LT Wang","year":"2024","unstructured":"Wang, L. T., Idris, A. H., Kisalu, N. K., Crompton, P. D. & Seder, R. A. Monoclonal antibodies to the circumsporozoite proteins as an emerging tool for malaria prevention. Nat. Immunol. 25, 1530\u20131545 (2024).","journal-title":"Nat. Immunol."},{"key":"1241_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/science.adr0510","volume":"387","author":"C Dacon","year":"2025","unstructured":"Dacon, C. et al. Protective antibodies target cryptic epitope unmasked by cleavage of malaria sporozoite protein. Science 387, eadr0510 (2025).","journal-title":"Science"},{"key":"1241_CR27","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","volume":"53","author":"LT Wang","year":"2020","unstructured":"Wang, L. T. et al. A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver. Immunity 53, 733\u2013744 (2020).","journal-title":"Immunity"},{"key":"1241_CR28","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1056\/NEJMoa2203067","volume":"387","author":"RL Wu","year":"2022","unstructured":"Wu, R. L. et al. Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria. N. Engl. J. Med. 387, 397\u2013407 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1241_CR29","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1056\/NEJMoa2312775","volume":"390","author":"K Kayentao","year":"2024","unstructured":"Kayentao, K. et al. Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria. N. Engl. J. Med. 390, 1549\u20131559 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1241_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00457-1","volume":"7","author":"L Jelinkova","year":"2022","unstructured":"Jelinkova, L. et al. A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model. npj Vaccines 7, 34 (2022).","journal-title":"npj Vaccines"},{"key":"1241_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38509-2","volume":"14","author":"GM Martin","year":"2023","unstructured":"Martin, G. M. et al. Structural basis of epitope selectivity and potent protection from malaria by PfCSP antibody L9. Nat. Commun. 14, 2815 (2023).","journal-title":"Nat. Commun."},{"key":"1241_CR32","doi-asserted-by":"crossref","unstructured":"Francian, A. et al. Virus-like particle-based vaccines targeting the Anopheles mosquito salivary protein, TRIO. bioRxiv (2024).","DOI":"10.1101\/2024.09.05.611467"},{"key":"1241_CR33","doi-asserted-by":"crossref","unstructured":"Mogus, A. T. et al. Virus-like particle based vaccines elicit neutralizing antibodies against the HIV-1 fusion peptide. Vaccines 8, 765 (2020).","DOI":"10.3390\/vaccines8040765"},{"key":"1241_CR34","doi-asserted-by":"crossref","unstructured":"Chackerian, B. & Peabody, D. S. Factors that govern the induction of long-lived antibody responses. Viruses 12, 74 (2020).","DOI":"10.3390\/v12010074"},{"key":"1241_CR35","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1056\/NEJMoa066092","volume":"357","author":"IJ Amanna","year":"2007","unstructured":"Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903\u20131915 (2007).","journal-title":"N. Engl. J. Med."},{"key":"1241_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-3055-9","volume":"18","author":"Y Flores-Garcia","year":"2019","unstructured":"Flores-Garcia, Y. et al. Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages. Malar. J. 18, 426 (2019).","journal-title":"Malar. J."},{"key":"1241_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00819-x","volume":"9","author":"E Locke","year":"2024","unstructured":"Locke, E. et al. Establishing RTS,S\/AS01 as a benchmark for comparison to next-generation malaria vaccines in a mouse model. npj Vaccines 9, 29 (2024).","journal-title":"npj Vaccines"},{"key":"1241_CR38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41591-023-02659-z","volume":"30","author":"KL Williams","year":"2024","unstructured":"Williams, K. L. et al. A candidate antibody drug for prevention of malaria. Nat. Med. 30, 117\u2013129 (2024).","journal-title":"Nat. Med."},{"key":"1241_CR39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.4512","volume":"24","author":"NK Kisalu","year":"2018","unstructured":"Kisalu, N. K. et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat. Med. 24, 408\u2013416 (2018).","journal-title":"Nat. Med."},{"key":"1241_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00274-4","volume":"6","author":"L Jelinkova","year":"2021","unstructured":"Jelinkova, L. et al. An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein. npj Vaccines 6, 13 (2021).","journal-title":"npj Vaccines"},{"key":"1241_CR41","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nm1350","volume":"12","author":"R Amino","year":"2006","unstructured":"Amino, R. et al. Quantitative imaging of Plasmodium transmission from mosquito to mammal. Nat. Med. 12, 220\u2013224 (2006).","journal-title":"Nat. Med."},{"key":"1241_CR42","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1074\/jbc.M116.754796","volume":"292","author":"AP Patra","year":"2017","unstructured":"Patra, A. P., Sharma, S. & Ainavarapu, S. R. Force spectroscopy of the plasmodium falciparum vaccine candidate circumsporozoite protein suggests a mechanically pliable repeat region. J. Biol. Chem. 292, 2110\u20132119 (2017).","journal-title":"J. Biol. Chem."},{"key":"1241_CR43","doi-asserted-by":"publisher","first-page":"26951","DOI":"10.1074\/jbc.M109.013706","volume":"284","author":"ML Plassmeyer","year":"2009","unstructured":"Plassmeyer, M. L. et al. Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. J. Biol. Chem. 284, 26951\u201326963 (2009).","journal-title":"J. Biol. Chem."},{"key":"1241_CR44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jmb.2011.03.072","volume":"409","author":"B Chackerian","year":"2011","unstructured":"Chackerian, B., Caldeira Jdo, C., Peabody, J. & Peabody, D. S. Peptide epitope identification by affinity selection on bacteriophage MS2 virus-like particles. J. Mol. Biol. 409, 225\u2013237 (2011).","journal-title":"J. Mol. Biol."},{"key":"1241_CR45","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jmb.2008.04.049","volume":"380","author":"DS Peabody","year":"2008","unstructured":"Peabody, D. S. et al. Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. J. Mol. Biol. 380, 252\u2013263 (2008).","journal-title":"J. Mol. Biol."},{"key":"1241_CR46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0022-1759(90)90029-U","volume":"132","author":"Y Aida","year":"1990","unstructured":"Aida, Y. & Pabst, M. J. Removal of endotoxin from protein solutions by phase separation using Triton X-114. J. Immunol. Methods 132, 191\u2013195 (1990).","journal-title":"J. Immunol. Methods"},{"key":"1241_CR47","doi-asserted-by":"publisher","first-page":"e107764","DOI":"10.1371\/journal.pone.0107764","volume":"9","author":"AR Noe","year":"2014","unstructured":"Noe, A. R. et al. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate. PLoS One 9, e107764 (2014).","journal-title":"PLoS One"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01241-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01241-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01241-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T09:07:02Z","timestamp":1757322422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01241-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1241"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01241-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.03.03.641239","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.C. has equity in Metaphore Biotechnologies. S.A.D. is affiliated with ViroVax LLC, which holds proprietary rights over the Cquim-MA adjuvant. F.Z. serves as an Associate Editor of this journal and had no role in the peer-review or decision to publish this manuscript. F.Z. declares no financial competing interests. All other authors (Y.N., A.F., Y.F-G., and B.T.R.) declare no competing financial or non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"176"}}